Phase 1a: First-in-Human Single Ascending Dose Study (NCT02951806) Study Title: "Safety, Tolerability, and Pharmacokinetics of Single Doses of Cagrilintide in Healthy Subjects" Status: Completed Phase: Phase 1a Enrollment: 48 healthy volunteers Study Period: 2016-2017 Location: Single center (Denmark) Design: Randomized, double-blind, placebo-controlled, single ascending dose Dose Range: 0.03-10 mg SC Primary Endpoints: Safety, tolerability, PK parameters Population: Healthy male subjects, BMI 20-28 Key Results: Pharmacokinetics: Terminal half-life 5-7 days across dose range
Understanding Weight Loss Doctors When it comes to weight loss, the type of doctor you choose can make a big difference in your journey
Opting for branded treatments ensures you receive thoroughly tested, high-quality drugs supported by significant clinical trials
However, the team did not look specifically at the childrens symptoms to see if any had improved, so further research is needed to determine this impact
Active during low blood sugar states
Numbers, time and neocortical neuronogenesis: a general developmental and evolutionary model
.webp)
